CTOs on the Move

Broad Institute

www.broadinstitute.org

 
The Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty. The culture and environment at the Broad is designed to encourage creativity and to engage all participants, regardless of role or seniority, in the mission of the Institute. Within this setting, researchers are empowered — both intellectually and technically — to confront even the most difficult biomedical challenges. The Institute`s organization is unique among biomedical research institutions. It encompasses three types of organizational units: core member laboratories, programs and platforms. Scientists ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Lila Lamar
Senior Information Security Program Manager Profile
David Corbin
Director, Campus Security Operations Profile
David Bernick
Sr. Director, CISO Profile
Elie Abouzeid
Director of Information Security and Compliance Profile

Similar Companies

Lybradyn Inc

Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pear Therapeutics

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions and is the leader in FDA-authorized prescription digital therapeutics.

Citra-Solv

Citra-Solv LLC is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.